The 17 most recent market catalysts affecting $BIAF, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
bioAffinity Technologies shares are trading higher after the company announced it is presenting two posters highlighting CyPath Lung at the 2026 NAVREF Annual Conference.
The announcement of presenting new data at a significant medical conference like NAVREF is a positive corporate catalyst for bioAffinity Technologies. It suggests progress in their…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
BioAffinity Technologies announced the grant of a Hong Kong patent for its CyPath Lung diagnostic, a noninvasive tool for assessing lung nodules. This patent, combined with a 2025 …
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
bioAffinity Technologies shares are trading higher after the company announced that the Hong Kong Intellectual Property Department has granted a patent for the proprietary platform technology for predicting the likelihood of lung cancer using flow cytometry and fluorescent markers to characterize cell populations in sputum.
The granting of a patent in Hong Kong for bioAffinity Technologies' lung cancer prediction platform is a significant corporate catalyst. It strengthens the company's intellectual p…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 55
Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum
bioAffinity Technologies announced the Hong Kong Intellectual Property Department granted a patent for its lung cancer detection technology. This is significant because it provides…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
bioAffinity Technologies shares are trading higher after the company announced it regained compliance with the Nasdaq.
The regaining of Nasdaq compliance is a significant positive catalyst for BioAffinity Technologies. It removes the immediate threat of delisting, which often deters institutional i…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
BioAffinity Advances Noninvasive CyPath Lung Test For Post-Treatment Monitoring
BioAffinity Technologies is advancing its CyPath Lung test for surveillance of lung cancer patients post-treatment, a critical area given the high recurrence rates and large popula…
Sep 1, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Tuesday's Intraday Session
This 8-K filing, generated by an automated content engine, highlights significant intraday price volatility across a selection of health care stocks. It's a snapshot of market acti…
Sep 1, 2026
Macro/Central Bank
Bearish
Impact 65
Crude Oil Surges 3%; ISM Manufacturing PMI Falls In August
The core of this filing is the decline in the ISM Manufacturing PMI, which came in below expectations. This suggests a potential slowdown in the manufacturing sector, a key indicat…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
bioAffinity Technologies shares are trading higher after the company announced that it is advancing the potential application of its CyPath Lung Test.
This headline indicates a positive corporate catalyst for bioAffinity Technologies. Advancing the potential application of its CyPath Lung Test suggests a broader market reach and …
Sep 1, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This filing, generated by Benzinga's automated content engine, reports on the pre-market trading activity of 12 health care stocks. It identifies six gainers and six losers, with s…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 65
bioAffinity Technologies Announces 1-For-15 Reverse Stock Split, Effective Aug. 24
bioAffinity Technologies is implementing a 1-for-15 reverse stock split. This corporate action reduces the number of outstanding shares and proportionally increases the stock price…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
bioAffinity Technologies shares are trading higher after the company announced a distribution agreement with AvMEDICAL.
The distribution agreement with AvMEDICAL is a direct positive catalyst for bioAffinity Technologies (BIAF). It signifies a crucial step in commercializing their products, potentia…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
bioAffinity Enters Into Distribution Agreement With AvMEDICAL Expanding bioAffinity's Commercial Reach Through AvMEDICAL's Existing Sales Team
bioAffinity Technologies (BIAF) has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business. This agreement is significant because it …
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 85
bioAffinity Technologies shares are trading lower after the company announced pricing of $4 million private placement offering priced at-the-market under Nasdaq rules.
The private placement offering, priced 'at-the-market,' indicates that new shares are being sold at or near the current trading price, which typically leads to dilution for existin…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 75
bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate
bioAffinity Technologies (BIAF) announced Q2 results showing a significant beat on both earnings per share and revenue estimates. The company's loss per share of $(0.64) was substa…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 55
bioAffinity Announces Publication Of Clinical Review And White Paper For Incorporating CyPath Lung Into Pulmonary Nodule Evaluation And Cancer Surveillance
bioAffinity announced the publication of a white paper and clinical review for its CyPath Lung test. This publication is significant as it provides a detailed examination of how th…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 65
bioAffinity, Pictor Collaborate To Integrate Flow Cytometry And Proteomic Analysis Platform To Analyze Immune Cell Populations And Cytokine Profiles Related To Airway Inflammation
bioAffinity Technologies (BIAF) has entered a collaboration with Pictor, Inc. to combine their expertise in flow cytometry and targeted proteomic analysis. This partnership is focu…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.